Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivectrade mark) for Advanced Stage Gastrointestinal Stromal Tumours.

Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivectrade mark) for Advanced Stage Gastrointestinal Stromal Tumours. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivectrade mark) for Advanced Stage Gastrointestinal Stromal Tumours. Abstract Text:

Skin toxicity is a common side-effect of treatment with imatinib mesylate (STI571, Glivectrade mark) in advanced gastrointestinal stromal tumours (GIST) and chronic myeloid leukaemia. The optimal duration of treatment with imatinib mesylate in GIST has not yet been established, as durable remissions have been observed in patients. It is, therefore, important to develop strategies to deal with common side-effects of what may be a long-term treatment. Here we report the case of a patient with advanced GIST who developed a cutaneous drug reaction secondary to imatinib mesylate and the various management options that may be employed depending upon the severity of the toxicity. The case and literature are discussed.

Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivectrade mark) for Advanced Stage Gastrointestinal Stromal Tumours. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivectrade mark) for Advanced Stage Gastrointestinal Stromal Tumours. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Sarcoma

VOLUME: 9

Page Numbers: 157-60

Journal Abbreviation:

ISSN: 1357-714X

DAY: 3

MONTH: 06

YEAR: 2005

Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivectrade mark) for Advanced Stage Gastrointestinal Stromal Tumours. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9709257

Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivectrade mark) for Advanced Stage Gastrointestinal Stromal Tumours. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivectrade mark) for Advanced Stage Gastrointestinal Stromal Tumours. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivectrade mark) for Advanced Stage Gastrointestinal Stromal Tumours.

AFFILIATION: Centre for Oncology and Applied Pharmacology University of Glasgow Glasgow Scotland.

Country: Egypt

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Sarcoma

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Management of Skin Toxicity Related to the Use of Imatinib Mesylate STI571, Glivectrade mark for Advanced Stage Gastrointestinal Stromal Tumours Related Publications

• A MONGOL CHILD WITHOUT TRISOMY G.
• A geographic mosaic of passive dispersal: population structure in the endemic Hawaiian amber snail Succinea caduca (Mighels, 1845).
• An atypical case of phenylketonuria.
• Audit response rates.
• Can size of spacer make a difference?
• Developmental aspects of mongolism.
• Diabetes and hearing impairment in the United States: audiometric evidence from the National Health and Nutrition Examination Survey, 1999 to 2004.
• Endometrial carcinoma: does the addition of intracavitary vault caesium to external beam therapy postoperatively result in improved control or increased morbidity?
• Ethnic differences in the ability of triglyceride levels to identify insulin resistance.
• Evaluation of the European Heart Failure Self-care Behaviour Scale in a United Kingdom population.
• Factors associated with the development of progressive massive fibrosis in British coalminers: a case-control study.
• Femoral artery complications after diagnostic procedures.
• Identification and guided treatment of ventricular dysfunction in general practice using blood B-type natriuretic peptide.
• Influence on the replacement value of some adrenal-cortex steroids of dietary sodium and synergism of steroids in lactating adrenalectomized rats.
• Intra-arterial transfusion in the treatment of severe injury.
• Kinetic studies of beta-galactosidase induction.
• Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivectrade mark) for Advanced Stage Gastrointestinal Stromal Tumours.
• NHS heart failure survey: a survey of acute heart failure admissions in England, Wales and Northern Ireland.
• Online reflective learning supported by student facilitators.
• Projections from the rostral mesencephalic reticular formation to the spinal cord. An HRP and autoradiographical tracing study in the cat.
• Pulmonary dysfunction in gold miners with reactive airways.
• Rituximab responsive immune thrombocytopenic purpura in an adult with underlying autoimmune lymphoproliferative syndrome due to a splice-site mutation (IVS7+2 T>C) affecting the Fas gene.
• Spontaneous intraperitoneal rupture of an infected hydronephrosis.
• Steroid excretion in mothers of mongols.
• Taboo: crossing the specialty barrier.
• The galactose tolerance test in phenylketonuria.
• The influence of age and sex on the life span of adrenalectomized rats.
• Trends in hospital admissions, in-hospital case fatality and population mortality from congenital heart disease in England, 1994 to 2004.
• Two tumours within a fractured skull.
• Urban and rural differences in the management of asthma amongst primary care physicians in Alberta.